The European Commission’s pharmaceutical sector enquiry: was it really worth €100 million?
This article was originally published in SRA
Executive Summary
The final report on the European Commission’s pharmaceutical sector enquiry has now been published and has reiterated many of the criticisms against the originator industry that were initially raised in the preliminary report. However, to recall a question posed by one of the UK’s senior patent judges, Lord Justice Robin Jacob, has it taught us anything we did not already know?Faraz Kermani, Informa Business Information analyst, reports.
You may also be interested in...
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.
EMA Acts To Freeze Drugs Linked to GVK Bio, Guards Against Shortages
EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.